NEUROSENSE THERAPEUTICS LTD
NRSNNASDAQTrading Snapshot
- Day Range
- $0.47 – $0.48
- 52-Week Range
- $0.39 – $1.98
- Volume
- $2.69B
- Avg Volume
- $2.57B
- Shares Outstanding
- 35.4M
- Next Earnings
- Oct 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $582,873
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.62
- Dividend Yield
- —
Why Investors Own NRSN
- ✓High-growth profile — revenue up -2.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 80% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About NEUROSENSE THERAPEUTICS LTD
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Celestica Inc (NYSE: CLS) exceeded analyst estimates with quarterly earnings of $2.54 per share and revenue of $4.7 billion, leading to a 4.7% jump in pre-market trading. Other top gainers include C3is, INLIF, and Polar Power. FIEE and KIDZ were among the top losers.
NeuroSense Intends To Proceed With Filing Of NDS To Health Canada For PrimeC For Treatment Of Amyotrophic Lateral Sclerosis, Following Constructive Pre-NDS Meeting
The planned submission follows alignment with Health Canada on the NDS pathway and is supported by additional PARADIGM data, including a survival benefit and consistent effects across PrimeC's multi-pathway